Meningiococcal MeningitisMenigiococcal meningitis is also called as “cerebrospinalfever” is an acute communicable diseaseI...
Causative AgentThe causative agent is N – Meningitides is a gram – vediplococciSeveral serotype have been identified viz g...
HostMan is the host of the diseaseSex: Both sex involved equallyAge: All age at risk but particularly the childrenImmunity...
Reservoir & Source Of The             InfectionInfected person are the reservoir either in the form of thecases or carrier...
Mode Of The TransmissionThe disease spread mainly by droplets infectionThe portal of the entry is the nasopharynx
Incubation PeriodIncubation period is usually 3 to 4 daysIt may vary from the 2 – 10 days
Prevention & Control1) Cases2) Carrier3) Contact4) Mass of the chemoprophylaxis5) Immunization6) Environmental measure
CasesTreatment with the antibiotic can save the lives of the 95%of the patients provided that it is started during the fir...
CarrierTreatment with the penicillin does not eradicate the carrierstateMore powerful antibiotics such as rifampicin are n...
ContactClose contact with the person with the confirmedmeningiococcal disease are at increase risk of the developingmening...
Mass ChemoprophylaxisThis is infect the mass medication of the total populationsome of the which are not infectedIt is rec...
ImmunizationEffective Vaccine prepared from the purified group A, groupC, group Y, or group W135 meningiococcal polysaccha...
Environmental MeasureImprove the housingPrevention of the overcrowding
Upcoming SlideShare
Loading in …5
×

Meningiococcal meningitis

466 views

Published on

This presentation is made by Dr Ashok Jaisingani

Published in: Health & Medicine, Business
  • Be the first to comment

Meningiococcal meningitis

  1. 1. Meningiococcal MeningitisMenigiococcal meningitis is also called as “cerebrospinalfever” is an acute communicable diseaseIt usually begin with the intense head ache, vomiting andstiff neck and progress to the coma within few hoursThe meningitis is part of the septicaemic processThe fatality of the untreated cases is about 80%With the early diagnosis and treatment case fatality ratedeclined to less than 10%
  2. 2. Causative AgentThe causative agent is N – Meningitides is a gram – vediplococciSeveral serotype have been identified viz group A, B, C, D,x, y, 29E, W135 etc.N – Meningitides is delicate organism it dies rapidly onexposure to heat and cold
  3. 3. HostMan is the host of the diseaseSex: Both sex involved equallyAge: All age at risk but particularly the childrenImmunity: Immunity appear only for 2- 3 yearsEnvironmental factors:Mostly occurs in dry and cold season
  4. 4. Reservoir & Source Of The InfectionInfected person are the reservoir either in the form of thecases or carrierCarrier rate is 70 – 80% in epidemics otherwise 5 – 30% ofthe population bears the organism in inter – epidemic periodSource Of The Infection:The organism is found in the nasopharynx, of the cases andcarrierThe clinical cases present a negligible source of the infectionMore often the infection cause mild or even unnoticeablesymptoms of the nasopharyngitis
  5. 5. Mode Of The TransmissionThe disease spread mainly by droplets infectionThe portal of the entry is the nasopharynx
  6. 6. Incubation PeriodIncubation period is usually 3 to 4 daysIt may vary from the 2 – 10 days
  7. 7. Prevention & Control1) Cases2) Carrier3) Contact4) Mass of the chemoprophylaxis5) Immunization6) Environmental measure
  8. 8. CasesTreatment with the antibiotic can save the lives of the 95%of the patients provided that it is started during the first 2 –days of the illnessPenicillin is the drug of the choiceIn penicillin allergic patients chloramphenical should besubstitutedTreatment of the cases has particularly no effect on theepidemiological pattern of the disease because it only reducethe fatality rate of the disease according to the treatmentefficiencyIsolation of the cases is of the limited usefulness
  9. 9. CarrierTreatment with the penicillin does not eradicate the carrierstateMore powerful antibiotics such as rifampicin are needed toeradicate the carrier state
  10. 10. ContactClose contact with the person with the confirmedmeningiococcal disease are at increase risk of the developingmeningiococcal illnessNearly One – third of the secondary cases occurs in the first4 – days
  11. 11. Mass ChemoprophylaxisThis is infect the mass medication of the total populationsome of the which are not infectedIt is recommended that mass chemoprophylaxis be restrictedto the closed and medically supervised communitiesMass treatment cause an immediate drop in the incidencerate of the meningitis and in the proportion in the carrierThe efficacy of this preventive measure depend to largeextent on the population carrier
  12. 12. ImmunizationEffective Vaccine prepared from the purified group A, groupC, group Y, or group W135 meningiococcal polysaccharideare now availableVaccine may be monovalent (A or C) or polyvalent (A-C, A-C-Y-etc)Immunity last for the three years, and booster every 3 – yearswould be reasonableThe vaccine is not recommended for use in infants andchildren under 2 – yearsThe vaccine is contraindicated in the pregnant women
  13. 13. Environmental MeasureImprove the housingPrevention of the overcrowding

×